{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:56:49Z","timestamp":1791262609051,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Heilongjiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["PL2025H217"],"award-info":[{"award-number":["PL2025H217"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110435","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:41:42Z","timestamp":1787848902000},"page":"110435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advances in the discovery of anti-breast cancer agents based on dual-target inhibition strategies"],"prefix":"10.1016","volume":"182","author":[{"given":"Guanghuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110435_bb0010","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0015","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110435_bb0030","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.3390\/cancers13215350","article-title":"Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer","volume":"13","author":"Shaath","year":"2021","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.bioorg.2026.110435_bb0035","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1470-2045(14)71188-X","article-title":"CDK4\/6 inhibitors in luminal breast cancer","volume":"16","author":"Gnant","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","article-title":"HER2 in breast cancer: a review and update","volume":"21","author":"Krishnamurti","year":"2014","journal-title":"Adv. Anat. Pathol."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110435_bb0050","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110435_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101965","article-title":"HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis","volume":"84","author":"Schettini","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jnci\/djz042","article-title":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade","volume":"112","author":"Prat","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110435_bb0065","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1021\/acs.jmedchem.0c01180","article-title":"Small-molecule drug discovery in triple negative breast cancer: current situation and future directions","volume":"64","author":"Liao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","article-title":"Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial","volume":"31","author":"Jiang","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0080","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110435_bb0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.onc.1207166","article-title":"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/ErbB2 kinase inhibitor GW572016","volume":"23","author":"Xia","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mds328","article-title":"Pertuzumab: new hope for patients with HER2-positive breast cancer","volume":"24","author":"Capelan","year":"2013","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110435_bb0105","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/molecules30143026","article-title":"Recent research advances in HER2-positive breast cancer concerning targeted therapy drugs","volume":"30","author":"Li","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110435_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol. Rev."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110435_bb0115","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.7150\/thno.72599","article-title":"SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor \u03b1-positive breast cancer cells","volume":"12","author":"Jin","year":"2022","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-025-01062-6","article-title":"PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2\u2212 breast cancer harbouring acquired ESR1 mutations","volume":"22","author":"Neven","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","article-title":"ESR1 F404 mutations and acquired resistance to Fulvestrant in ESR1-mutant breast cancer","volume":"14","author":"Kingston","year":"2024","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0130","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.18632\/aging.204110","article-title":"LINC00094\/miR-19a-3p\/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway","volume":"14","author":"Xiang","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110435_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413376","article-title":"The biological roles and clinical applications of the PI3K\/AKT pathway in targeted therapy resistance in HER2-positive breast cancer: a comprehensive review","volume":"25","author":"Zhong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10020-023-00736-0","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.20517\/cdr.2022.48","article-title":"Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer","volume":"5","author":"Eli","year":"2022","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.bioorg.2026.110435_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108665","article-title":"Design, synthesis and evaluation of styrylquinolinium derivatives targeting c-MYC \/BCL2 G-quadruplexes against breast cancer","volume":"163","author":"Gao","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110435_bb0170","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110435_bb0175","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/med.22057","article-title":"Rethinking therapeutic strategies of dual-target drugs: an update on pharmacological small-molecule compounds in cancer","volume":"44","author":"Yang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110435_bb0180","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tips.2024.04.008","article-title":"Defeating MYC with drug combinations or dual-targeting drugs","volume":"45","author":"Thompson","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110435_bb0185","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"Suppl. 6","key":"10.1016\/j.bioorg.2026.110435_bb0195","doi-asserted-by":"crossref","first-page":"vi26","DOI":"10.1093\/annonc\/mdm220","article-title":"Lapatinib in breast cancer","volume":"18","author":"Bilancia","year":"2007","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","article-title":"Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial","volume":"26","author":"Bonnefoi","year":"2025","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0205","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0210","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.02.006","article-title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety","volume":"43","author":"Palmer","year":"2025","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110435_bb0225","doi-asserted-by":"crossref","first-page":"26085","DOI":"10.1021\/acs.jmedchem.5c02137","article-title":"Discovery of Atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor","volume":"68","author":"Gallego","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast Cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110435_bb0235","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast Cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110435_bb0240","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","article-title":"Momelotinib: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0245","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s12951-022-01703-3","article-title":"Review targeted drug delivery systems for norcantharidin in cancer therapy","volume":"20","author":"Zhai","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110435_bb0250","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A phase I study of foretinib, a multi-targeted inhibitor of c-met and vascular endothelial growth factor receptor 2","volume":"16","author":"Eder","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-017-0836-3","article-title":"A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer","volume":"19","author":"Chia","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0260","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.7150\/thno.36182","article-title":"Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts","volume":"10","author":"Coussy","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cels.2019.11.001","article-title":"Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast Cancer cells","volume":"10","author":"Chopra","year":"2020","journal-title":"Cell Syst."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110435_bb0270","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1158\/1078-0432.CCR-15-2158","article-title":"UM-164: a potent c-Src\/p38 kinase inhibitor with in vivo activity against triple-negative breast Cancer","volume":"22","author":"Gilani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.bioorg.2026.110435_bb0275","doi-asserted-by":"crossref","first-page":"7949","DOI":"10.1073\/pnas.1720000115","article-title":"Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth","volume":"115","author":"Ren","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110435_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107377","article-title":"BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer","volume":"208","author":"Liu","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0285","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1535-7163.MCT-15-0096","article-title":"Antitumor activity of KW-2450 against triple-negative breast Cancer by inhibiting Aurora a and B kinases","volume":"14","author":"Kai","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"8_Supplement","key":"10.1016\/j.bioorg.2026.110435_bb0290","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1158\/1538-7445.AM10-5779","article-title":"Abstract 5779: the discovery of the potent and selective PI3K\/mTOR dual inhibitor PF-04691502 through structure-based drug design","volume":"70","author":"Cheng","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110435_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112954","article-title":"Small-molecule inhibitors of breast cancer-related targets: potential therapeutic agents for breast cancer","volume":"210","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110435_bb0300","doi-asserted-by":"crossref","first-page":"26085","DOI":"10.1021\/acs.jmedchem.5c02137","article-title":"Discovery of Atirmociclib (PF-07220060): a potent and selective CDK4 inhibitor","volume":"68","author":"Gallego","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41422-025-01117-4","article-title":"Selective CDK4 inhibition holds promise for breast cancer","volume":"35","author":"Beltr\u00e1n-Visiedo","year":"2025","journal-title":"Cell Res."},{"issue":"12_Supplement","key":"10.1016\/j.bioorg.2026.110435_bb0310","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P5-07-28","article-title":"Abstract P5-07-28: the next-generation CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+\/HER2+ metastatic breast cancer","volume":"31","author":"Giordana","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110435_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104644","article-title":"90P effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+\/HER2\u2212 metastatic breast cancer (mBC)","volume":"10","author":"Schmid","year":"2025","journal-title":"ESMO Open."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110435_bb0320","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","article-title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","volume":"26","author":"Escriv\u00e1-de-Romani","year":"2025","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110435_bb0325","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/2159-8290.CD-23-0838","article-title":"Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts","volume":"14","author":"DiPeri","year":"2024","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110435_bb0330","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-025-02163-3","article-title":"Zanidatamab: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0335","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0340","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2021","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0345","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178540","article-title":"Epigenetic regulation of tumor immunity","volume":"134","author":"Pang","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0350","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","article-title":"m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.495","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7986","key":"10.1016\/j.bioorg.2026.110435_bb0365","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-023-06682-5","article-title":"Epigenetic regulation during cancer transitions across 11 tumour types","volume":"623","author":"Terekhanova","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110435_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.401","article-title":"Epigenetic regulation in lung cancer","volume":"4","author":"Ramazi","year":"2023","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0375","first-page":"376","article-title":"Cancer epigenetics in clinical practice","volume":"73","author":"Davalos","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110435_bb0380","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.bioorg.2026.110435_bb0385","doi-asserted-by":"crossref","first-page":"19022","DOI":"10.1021\/acs.jmedchem.5c01092","article-title":"Design, synthesis, and biological evaluation of Quinoline-based Hydroxamic acid derivatives as dual DNMT and HDAC inhibitors with potent anti-breast Cancer activity","volume":"68","author":"Lin","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11\u221212","key":"10.1016\/j.bioorg.2026.110435_bb0390","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s10495-024-02023-7","article-title":"Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer","volume":"29","author":"Sethy","year":"2024","journal-title":"Apoptosis"},{"issue":"18","key":"10.1016\/j.bioorg.2026.110435_bb0395","doi-asserted-by":"crossref","first-page":"12346","DOI":"10.1021\/acs.jmedchem.2c01058","article-title":"Discovery of a novel G-Quadruplex and histone deacetylase (HDAC) dual-targeting agent for the treatment of triple-negative breast Cancer","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0400","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1093\/nar\/gkad365","article-title":"A new G-quadruplex-specific photosensitizer inducing genome instability in cancer cells by triggering oxidative DNA damage and impeding replication fork progression","volume":"51","author":"Deiana","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-2-31","article-title":"Vorinostat in solid and hematologic malignancies","volume":"2","author":"Siegel","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"34","key":"10.1016\/j.bioorg.2026.110435_bb0410","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1038\/s41388-021-01931-1","article-title":"HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer","volume":"40","author":"Clements","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0415","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel Pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110435_bb0420","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of Fedratinib for treatment of both hematologic malignancies and solid cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0425","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41467-018-04607-9","article-title":"Combined rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer","volume":"9","author":"Nam","year":"2018","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110435_bb0430","doi-asserted-by":"crossref","first-page":"20619","DOI":"10.1021\/acs.jmedchem.4c02183","article-title":"Discovery of the first-in-class dual-target ROCK\/HDAC inhibitor with potent antitumor efficacy in vivo that trigger antitumor immunity","volume":"67","author":"Mao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126348","article-title":"Identification of a novel PAK1\/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer","volume":"251","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2026.110435_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116393","article-title":"Dual-target inhibitors based on ERalpha: novel therapeutic approaches for endocrine resistant breast cancer","volume":"270","author":"Xiong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0445","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10549-011-1364-y","article-title":"Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy","volume":"130","author":"Thomas","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110435_bb0450","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm400467w","article-title":"Histone deacetylase inhibitors equipped with estrogen receptor modulation activity","volume":"56","author":"Gryder","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0455","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/acs.jmedchem.5c03005","article-title":"Approved steroidal drugs (2000-2025): a medicinal chemistry perspective","volume":"69","author":"Zhu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113870","article-title":"Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs\/HDAC inhibitors for the treatment of breast cancer","volume":"226","author":"Luo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106459","article-title":"Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERalpha degraders and HDAC inhibitors","volume":"134","author":"Xiong","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110435_bb0470","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41388-026-03681-4","article-title":"BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1+ macrophage-mediated immune evasion in triple-negative breast cancer","volume":"45","author":"Diao","year":"2026","journal-title":"Oncogene"},{"issue":"7504","key":"10.1016\/j.bioorg.2026.110435_bb0475","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110435_bb0480","doi-asserted-by":"crossref","first-page":"18025","DOI":"10.1021\/acs.jmedchem.1c01382","article-title":"Discovery of novel dual-target inhibitor of Bromodomain-containing protein 4\/casein kinase 2 inducing apoptosis and autophagy-associated cell death for triple-negative breast Cancer therapy","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110435_bb0485","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/0008-5472.CAN-23-1749","article-title":"Cotargeting CDK4\/6 and BRD4 promotes senescence and Ferroptosis sensitivity in Cancer","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.bioorg.2026.110435_bb0490","doi-asserted-by":"crossref","first-page":"21186","DOI":"10.1021\/acs.jmedchem.4c01976","article-title":"Discovery of dual CDK6\/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of Ferroptosis in triple-negative breast Cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0495","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17460441.2021.1850686","article-title":"Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?","volume":"16","author":"Shalini","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110435_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116246","article-title":"Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders","volume":"224","author":"Yang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0505","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/emboj\/21.4.514","article-title":"C-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis","volume":"21","author":"Furstoss","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.110435_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116009","article-title":"Design and synthesis of dual BRD4\/Src inhibitors for treatment of triple-negative breast cancer","volume":"264","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110435_bb0515","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm200903z","article-title":"Optimization of cellular activity of G9a inhibitors 7-Aminoalkoxy-quinazolines","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"27","key":"10.1016\/j.bioorg.2026.110435_bb0520","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1073\/pnas.1618706114","article-title":"G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis","volume":"114","author":"Casciello","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.110435_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2026.1790894","article-title":"Histone methyltransferase G9a crosstalks with H3K36 histone methyltransferases NSD3 and SETD2 to mediate gene activation","volume":"14","author":"Shah","year":"2026","journal-title":"Front. Cell Dev. Biol."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110435_bb0530","doi-asserted-by":"crossref","first-page":"16072","DOI":"10.1021\/acs.jmedchem.4c00640","article-title":"Discovery of a highly potent lysine methyltransferases G9a\/NSD2 dual inhibitor to treat solid tumors","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0535","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","article-title":"Synthetic lethal strategies for the development of cancer therapeutics","volume":"22","author":"Ngoi","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110435_bb0540","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/s41388-021-01744-2","article-title":"Exploiting synthetic lethality to target BRCA1\/2-deficient tumors: where we stand","volume":"40","author":"Patel","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0545","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41588-023-01557-x","article-title":"Complex synthetic lethality in cancer","volume":"55","author":"Ryan","year":"2023","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0550","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0555","first-page":"31","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic","volume":"61","author":"Yap","year":"2011","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110435_bb0560","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast Cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0565","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","volume":"37","author":"Yamaguchi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110435_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116054","article-title":"Dual target PARP1\/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy","volume":"265","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0575","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/med.21859","article-title":"Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives","volume":"42","author":"Feng","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110435_bb0580","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1021\/acs.jcim.4c01421","article-title":"Combining data-driven and structure-based approaches in designing dual PARP1-BRD4 inhibitors for breast Cancer treatment","volume":"64","author":"Feng","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0585","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110435_bb0590","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-Hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and Lead to synthetic lethality for triple-negative breast Cancer therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0595","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting Bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0600","doi-asserted-by":"crossref","DOI":"10.1002\/cbin.70157","article-title":"Synergistic combinations for improved therapeutic outcomes in triple negative breast Cancer","volume":"50","author":"Jha","year":"2026","journal-title":"Cell Biol. Int."},{"issue":"29","key":"10.1016\/j.bioorg.2026.110435_bb0605","article-title":"Novel ATR\/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast Cancer models","volume":"12","author":"Gao","year":"2025","journal-title":"Adv Sci (Weinh)."},{"key":"10.1016\/j.bioorg.2026.110435_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117160","article-title":"A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase","volume":"241","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110435_bb0615","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.3390\/ijms23073555","article-title":"Cyclin-dependent kinase synthetic lethality partners in DNA damage response","volume":"23","author":"Kciuk","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0620","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ijo.2013.2240","article-title":"The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition","volume":"44","author":"Xia","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110435_bb0625","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP inhibitors: extending benefit beyond BRCA-mutant cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0630","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","article-title":"The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110435_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0640","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0645","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","article-title":"Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of Wnt\/\u03b2-catenin signaling pathway for the treatment of BRCA wild-type TNBC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115648","article-title":"Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0655","article-title":"PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110435_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115943","article-title":"Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer","volume":"264","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113054","article-title":"Discovery of novel PARP\/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer","volume":"213","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110435_bb0670","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1021\/acs.jmedchem.3c00640","article-title":"Discovery, synthesis, and evaluation of novel dual inhibitors of a vascular endothelial growth factor receptor and poly(ADP-ribose) polymerase for BRCA wild-type breast Cancer therapy","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118887","article-title":"Discovery of an orally bioavailable selenium-containing Poltheta inhibitor with a dual mechanism of DNA damage and immune activation for HR-deficient cancers","volume":"313","author":"Ma","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110435_bb0680","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual Poltheta\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0685","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1021\/acs.jmedchem.0c02202","article-title":"New Dibenzoquinoxalines inhibit triple-negative breast Cancer growth by dual targeting of topoisomerase 1 and the c-MYC G-Quadruplex","volume":"64","author":"Hu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0690","author":"Tiang"},{"key":"10.1016\/j.bioorg.2026.110435_bb0695","doi-asserted-by":"crossref","unstructured":"[139]Berroyer A, Kim N. The functional consequences of eukaryotic topoisomerase 1 interaction with G-quadruplex DNA. Genes 2020;11(2):193. Doi: https:\/\/doi.org\/10.3390\/genes11020193.","DOI":"10.3390\/genes11020193"},{"issue":"S3","key":"10.1016\/j.bioorg.2026.110435_bb0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-suppl_3-10","article-title":"Dual kinase inhibition in the treatment of breast Cancer: initial experience with the EGFR\/ErbB-2 inhibitor Lapatinib","volume":"9","author":"Burris","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0705","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-024-49816-7","article-title":"Inhibition of topoisomerase 2 catalytic activity impacts the integrity of heterochromatin and repetitive DNA and leads to interlinks between clustered repeats","volume":"15","author":"Amoiridis","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110435_bb0710","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1101\/gr.211615.116","article-title":"Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci","volume":"27","author":"Yu","year":"2017","journal-title":"Genome Res."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110435_bb0715","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2165\/00003495-200767140-00006","article-title":"EGFR, HER2 and VEGF pathways: validated targets for cancer treatment","volume":"67","author":"Press","year":"2007","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110435_bb0720","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/med.20070","article-title":"Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development","volume":"26","author":"Kamath","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110435_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105469","article-title":"Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR\/HER-2 dual-target inhibitors against cancer growth and angiogenesis","volume":"119","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107686","article-title":"Design, synthesis and biological evaluation of novel quinazoline-derived EGFR\/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents","volume":"151","author":"Hao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118679","article-title":"Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR\/Aurora kinase inhibitors against hepatocellular and breast carcinomas","volume":"192","author":"Anwer","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110435_bb0740","article-title":"Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110435_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142586","article-title":"Discovery of new thieno[2,3-d]pyrimidine-based dual VEGFR-2 and EGFR inhibitors for enhanced therapeutic efficacy in breast cancer","volume":"1341","author":"Yousef","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110435_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154010","article-title":"PI3K\/Akt\/mTOR signaling pathway in cancer stem cells","volume":"237","author":"Karami fath","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110435_bb0755","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110435_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112954","article-title":"Small-molecule inhibitors of breast cancer-related targets: potential therapeutic agents for breast cancer","volume":"210","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113537","article-title":"XS-2, a novel potent dual PI3K\/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer","volume":"155","author":"Xu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0770","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-025-02342-4","article-title":"Signaling pathways and targeted interventions for precancers","volume":"11","author":"Yang","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0775","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/med.21867","article-title":"Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases","volume":"42","author":"Wang","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0780","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14756366.2020.1862101","article-title":"Novel oxindole\/benzofuran hybrids as potential dual CDK2\/GSK-3beta inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies","volume":"36","author":"Eldehna","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110435_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117486","article-title":"Aromatic nitroolefin with inhibition efficacy in triple-negative breast cancer cells by dual targeting RXRalpha and tubulins","volume":"289","author":"Qu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0790","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1158\/0008-5472.CAN-14-2435","article-title":"Nitrostyrene derivatives act as RXR\u03b1 ligands to inhibit TNF\u03b1 activation of NF-\u03baB","volume":"75","author":"Zeng","year":"2015","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110435_bb0795","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The theory of tumor ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0800","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0805","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110435_bb0810","doi-asserted-by":"crossref","first-page":"14824","DOI":"10.1021\/acs.jmedchem.3c01424","article-title":"4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a novel carbonic anhydrase and Wnt\/beta-catenin signaling pathway dual-targeting inhibitor with potent activity against multidrug resistant cancer cells","volume":"66","author":"Masci","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0815","doi-asserted-by":"crossref","DOI":"10.3390\/cells14100693","article-title":"Cooperative role of carbonic anhydrase IX\/XII in driving tumor invasion and metastasis: a novel targeted therapeutic strategy","volume":"14","author":"Yang","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0820","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","article-title":"Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy","volume":"24","author":"Wu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"47","key":"10.1016\/j.bioorg.2026.110435_bb0825","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/s41388-023-02844-x","article-title":"Biophysics in tumor growth and progression: from single mechano-sensitive molecules to mechanomedicine","volume":"42","author":"Xin","year":"2023","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110435_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bioorg.2026.110435_bb0835","series-title":"Tumor microenvironment: Non-hematopoietic cells","first-page":"15","article-title":"Fibroblasts in the tumor microenvironment","author":"Truffi","year":"2020"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0840","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2015.10.027","article-title":"Metabolic exchanges within tumor microenvironment","volume":"380","author":"Chiarugi","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0845","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0850","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-023-01748-4","article-title":"Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110435_bb0855","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41401-021-00840-z","article-title":"Therapeutic efficacy and mechanism of CD73-TGFbeta dual-blockade in a mouse model of triple-negative breast cancer","volume":"43","author":"Xing","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0860","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12929-022-00859-2","article-title":"Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?","volume":"29","author":"Kuo","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0865","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0870","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12964-023-01398-5","article-title":"Interplay of oxidative stress, cellular communication and signaling pathways in cancer","volume":"22","author":"Iqbal","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.110435_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118107","article-title":"Dual inhibition of carbonic anhydrase IX and glutathione peroxidase 4 as a novel strategy for ferroptosis-induced tumor cell death","volume":"300","author":"Renzi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110435_bb0880","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2026.2671683","article-title":"Molecular understanding for therapeutic targeting of hypoxia in breast cancer","volume":"30","author":"Angeli","year":"2026","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0885","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","article-title":"GPX4 in cell death, autophagy, and disease","volume":"19","author":"Xie","year":"2023","journal-title":"Autophagy"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0890","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1021\/acs.jmedchem.5c00126","article-title":"Discovery of Diaryl Piperidone-sulfonamide as a novel dual-target inhibitor of STAT3\/CAIX inducing Ferroptosis in triple-negative breast Cancer cells","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110435_bb0895","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1021\/acs.jmedchem.1c01099","article-title":"Discovery of novel anti-breast-Cancer inhibitors by synergistically antagonizing microtubule polymerization and aryl hydrocarbon receptor expression","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110435_bb0900","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0905","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/13543776.2023.2291390","article-title":"Development of tubulin polymerization inhibitors as anticancer agents","volume":"33","author":"Peerzada","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0910","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12940-020-00670-2","article-title":"Environmental chemicals, breast cancer progression and drug resistance","volume":"19","author":"Koual","year":"2020","journal-title":"Environ. Health"},{"issue":"14","key":"10.1016\/j.bioorg.2026.110435_bb0915","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.7150\/thno.72941","article-title":"Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention","volume":"12","author":"Epshtein","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110435_bb0920","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-021-00989-z","article-title":"Nitric oxide-releasing micelles with intelligent targeting for enhanced anti-tumor effect of cisplatin in hypoxia","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110435_bb0925","doi-asserted-by":"crossref","first-page":"13089","DOI":"10.1021\/acs.jmedchem.4c01070","article-title":"Discovery of NO donor-Aurovertin hybrids as dual ferroptosis and apoptosis inducers for treating triple negative breast cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110435_bb0930","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.gendis.2020.12.005","article-title":"Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: an update","volume":"9","author":"Mohanty","year":"2022","journal-title":"Genes & diseases."},{"key":"10.1016\/j.bioorg.2026.110435_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102496","article-title":"Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer","volume":"112","author":"Falato","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110435_bb0940","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110435_bb0945","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1021\/acs.jmedchem.4c00196","article-title":"Discovery of novel ERalpha and aromatase dual-targeting PROTAC degraders to overcome endocrine-resistant breast Cancer","volume":"67","author":"Xin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110435_bb0950","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20177678","article-title":"Estrogen-dependent control and cell-to-cell variability of transcriptional bursting","volume":"14","author":"Fritzsch","year":"2018","journal-title":"Mol. Syst. Biol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110435_bb0955","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1158\/0008-5472.CAN-15-2910","article-title":"Estrogen receptor \u03b1 promotes breast cancer by reprogramming choline metabolism","volume":"76","author":"Jia","year":"2016","journal-title":"Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826009715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:36:45Z","timestamp":1791261405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826009715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":191,"alternative-id":["S0045206826009715"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110435","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the discovery of anti-breast cancer agents based on dual-target inhibition strategies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110435"}}